This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Giuliano, K. A. Articles by Taylor, D. L. Search for Related Content PubMed PubMed Citation Articles by Giuliano, K. A. Articles by Taylor, D. L. Social Bookmarking                   What's this?

High-Content Screening with siRNA Optimizes a Cell Biological Approach to Drug Discovery: Defining the Role of P53 Activation in the Cellular Response to Anticancer Drugs

Yih-Tai Chen

D. Lansing Taylor

Deciphering the effects of compounds on molecular events within living cells is becoming an increasingly important component of drug discovery. In a model application of the industrial drug discovery process, the authors profiled a panel of 22 compounds using hierarchical cluster analysis of multiparameter high-content screening measurements from nearly 500,000 cells per microplate. RNAi protein knockdown methodology was used with high-content screening to dissect the effects of 2 anticancer drugs on multiple target activities. Camptothecin activated p53 in A549 lung carcinoma cells pretreated with scrambled siRNA, exhibited concentration-dependent cell cycle blocks, and induced moderate microtubule stabilization. Knockdown of camptothecin-induced p53 protein expression with p53 siRNA inhibited the G₁/S blocking activity of the drug and diminished its microtubule-stabilizing activity. Paclitaxel activated p53 protein at low concentrations but exhibited G₂/M cell cycle blocking activity at higher concentrations where microtubules were stabilized. In cells treated with p53 siRNA, paclitaxel failed to activate p53 protein, but the knockdown did not have a significant effect on the ability of paclitaxel to stabilize microtubules or induce a G₂/M cell cycle block. Thus, this model application of the use of RNAi technology within the context of high-content screening shows the potential to provide massive amounts of combinatorial cell biological information on the temporal and spatial responses that cells mount to treatment by promising therapeutic candidates.

Key Words: cell-based assays • RNA inhibition • high-content profiling • high-throughput screening • cluster analysis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				O. Durr, F. Duval, A. Nichols, P. Lang, A. Brodte, S. Heyse, and D. Besson Robust Hit Identification by Quality Assurance and Multivariate Data Analysis of a High-Content, Cell-Based Assay J Biomol Screen, December 1, 2007; 12(8): 1042 - 1049. [Abstract] [PDF]

				J. P. Plastaras, S.-H. Kim, Y. Y. Liu, D. T. Dicker, J. F. Dorsey, J. McDonough, G. Cerniglia, R. R. Rajendran, A. Gupta, A. K. Rustgi, et al. Cell Cycle Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation Cancer Res., October 1, 2007; 67(19): 9443 - 9454. [Abstract] [Full Text] [PDF]

				C. J. Wilson, Y. Si, C. M. Thompsons, A. Smellie, M. A. Ashwell, J.-F. Liu, P. Ye, D. Yohannes, and S.-C. Ng Identification of a Small Molecule That Induces Mitotic Arrest Using a Simplified High-Content Screening Assay and Data Analysis Method J Biomol Screen, February 1, 2006; 11(1): 21 - 28. [Abstract] [PDF]

				A. Vogt, A. Tamewitz, J. Skoko, R. P. Sikorski, K. A. Giuliano, and J. S. Lazo The Benzo[c]phenanthridine Alkaloid, Sanguinarine, Is a Selective, Cell-active Inhibitor of Mitogen-activated Protein Kinase Phosphatase-1 J. Biol. Chem., May 13, 2005; 280(19): 19078 - 19086. [Abstract] [Full Text] [PDF]